MetaVia (MTVA) Competitors $1.09 +0.07 (+6.86%) As of 10/15/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock MTVA vs. SPRB, ORMP, CNTX, CNTB, ALXO, IPA, QNCX, ANEB, ADAG, and IFRXShould you be buying MetaVia stock or one of its competitors? The main competitors of MetaVia include Spruce Biosciences (SPRB), Oramed Pharmaceuticals (ORMP), Context Therapeutics (CNTX), Connect Biopharma (CNTB), ALX Oncology (ALXO), ImmunoPrecise Antibodies (IPA), Quince Therapeutics (QNCX), Anebulo Pharmaceuticals (ANEB), Adagene (ADAG), and InflaRx (IFRX). These companies are all part of the "pharmaceutical products" industry. MetaVia vs. Its Competitors Spruce Biosciences Oramed Pharmaceuticals Context Therapeutics Connect Biopharma ALX Oncology ImmunoPrecise Antibodies Quince Therapeutics Anebulo Pharmaceuticals Adagene InflaRx MetaVia (NASDAQ:MTVA) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment. Does the media prefer MTVA or SPRB? In the previous week, Spruce Biosciences had 1 more articles in the media than MetaVia. MarketBeat recorded 4 mentions for Spruce Biosciences and 3 mentions for MetaVia. Spruce Biosciences' average media sentiment score of 0.66 beat MetaVia's score of 0.63 indicating that Spruce Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MetaVia 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spruce Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, MTVA or SPRB? MetaVia has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.47, meaning that its stock price is 147% more volatile than the S&P 500. Is MTVA or SPRB more profitable? Spruce Biosciences' return on equity of -177.45% beat MetaVia's return on equity.Company Net Margins Return on Equity Return on Assets MetaViaN/A -212.00% -107.21% Spruce Biosciences N/A -177.45%-118.06% Which has higher earnings and valuation, MTVA or SPRB? MetaVia has higher earnings, but lower revenue than Spruce Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetaViaN/AN/A-$27.59MN/AN/ASpruce Biosciences$1.30M68.82-$53.04M-$86.21-1.85 Do institutionals and insiders have more ownership in MTVA or SPRB? 1.4% of MetaVia shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 0.8% of MetaVia shares are owned by insiders. Comparatively, 6.9% of Spruce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts recommend MTVA or SPRB? MetaVia presently has a consensus price target of $7.50, indicating a potential upside of 588.07%. Spruce Biosciences has a consensus price target of $131.25, indicating a potential downside of 17.48%. Given MetaVia's stronger consensus rating and higher possible upside, equities analysts plainly believe MetaVia is more favorable than Spruce Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Spruce Biosciences 1 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.86 SummarySpruce Biosciences beats MetaVia on 7 of the 12 factors compared between the two stocks. Get MetaVia News Delivered to You Automatically Sign up to receive the latest news and ratings for MTVA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTVA vs. The Competition Export to ExcelMetricMetaViaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.68M$3.37B$6.11B$10.46BDividend YieldN/A2.30%5.73%4.77%P/E RatioN/A22.7785.3627.36Price / SalesN/A467.74602.77132.73Price / CashN/A46.7037.4661.86Price / Book1.1810.5512.426.81Net Income-$27.59M-$52.58M$3.32B$276.80M7 Day Performance5.83%0.09%0.57%0.42%1 Month Performance-18.05%15.61%10.52%7.86%1 Year PerformanceN/A15.13%72.99%41.24% MetaVia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTVAMetaVia2.8196 of 5 stars$1.09+6.9%$7.50+588.1%N/A$24.68MN/A0.008SPRBSpruce Biosciences0.7272 of 5 stars$160.07-12.3%$131.25-18.0%+353.9%$102.56M$4.91M0.0020Analyst ForecastGap DownORMPOramed Pharmaceuticals1.2175 of 5 stars$2.39-3.6%N/A-3.4%$101.69M$1.34M-6.8310High Trading VolumeCNTXContext Therapeutics3.2585 of 5 stars$1.14+0.9%$5.20+356.1%-31.3%$101.37MN/A0.007Gap UpCNTBConnect Biopharma3.4088 of 5 stars$1.82+2.2%$7.00+284.6%+48.4%$99.18M$26.03M0.00110Positive NewsALXOALX Oncology3.9806 of 5 stars$1.97+7.7%$3.30+67.5%+6.4%$98MN/A0.0040IPAImmunoPrecise Antibodies1.0405 of 5 stars$2.10+8.5%$4.00+90.9%+267.5%$96.68M$17.59M-3.0880Gap UpQNCXQuince Therapeutics3.3863 of 5 stars$1.92+7.9%$8.14+324.1%+156.1%$95.61MN/A-1.7660ANEBAnebulo Pharmaceuticals2.9721 of 5 stars$2.30-0.4%$5.50+139.1%+43.2%$94.91MN/A-8.854Gap UpADAGAdagene2.5174 of 5 stars$1.96-1.8%$7.00+258.1%-25.1%$93.79M$100K0.00260Gap DownHigh Trading VolumeIFRXInflaRx2.3694 of 5 stars$1.47+6.5%$6.20+321.8%-15.5%$92.64M$180K0.0060Positive NewsAnalyst Forecast Related Companies and Tools Related Companies SPRB Alternatives ORMP Alternatives CNTX Alternatives CNTB Alternatives ALXO Alternatives IPA Alternatives QNCX Alternatives ANEB Alternatives ADAG Alternatives IFRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTVA) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredBuy this stock before Tesla’s November 6 announcementThe End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MetaVia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MetaVia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
